Biogen, the world's largest biotech focused on brain diseases, is adding two experimental medicines to its arsenal through a collaboration with a fellow Cambridge, Massachusetts-based drugmaker, Sage Therapeutics, that could be worth more than $3 billion.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,